id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2005-D-0208-0006,FDA,FDA-2005-D-0208,"Reference 2 - FDA Blood Products Advisory Committee Meeting, March 2000 [FDA-2005-D-0208-0004] - Transcript",Supporting & Related Material,REF-Reference Material (external attachments),2008-07-18T04:00:00Z,2008,7,,,2008-07-18T20:39:43Z,,0,0,090000648067609f
FDA-2005-D-0208-0007,FDA,FDA-2005-D-0208,"Reference 5 - Draft Guidance for Industry General Considerations for Pediatric Pharmacokinetic Studies for Drugs and Biological Products, November 1998 [FDA-2005-D-0208-0004] - Draft Guidance Document",Supporting & Related Material,REF-Reference (internal unless indicated),2008-07-18T04:00:00Z,2008,7,,,2008-07-18T20:40:36Z,,0,0,0900006480676155
FDA-2005-D-0208-0014,FDA,FDA-2005-D-0208,Reference 4 - Background Material  for NAD1[FDA-2005-D-0208-0002],Supporting & Related Material,BKG-Background Material,2008-07-18T04:00:00Z,2008,7,,,2008-07-20T05:27:20Z,,0,0,0900006480441243
FDA-2005-D-0208-0009,FDA,FDA-2005-D-0208,"Reference 17 - Guidance for Industry ""Community Acquired Pneumonia - Developing Antimicrobial Drugs for Treatment [FDA-2005-D-0208-0004] - Draft Guidance Document",Supporting & Related Material,REF-Reference (internal unless indicated),2008-07-18T04:00:00Z,2008,7,,,2008-07-18T20:50:33Z,,0,0,0900006480676a57
FDA-2005-D-0208-0011,FDA,FDA-2005-D-0208,Reference 1 - Background Material  for NAD1[FDA-2005-D-0208-0002] - Draft Guidance Document,Supporting & Related Material,BKG-Background Material,2008-07-18T04:00:00Z,2008,7,,,2008-07-18T04:58:03Z,,0,0,0900006480441246
FDA-2005-D-0208-0008,FDA,FDA-2005-D-0208,"Reference 16 - Guidance for Industry ""Acute Bacterial Meningitis - Developing Antimicrobial Drugs for Treatment [FDA-2005-D-0208-0004] - Draft Guidance Document",Supporting & Related Material,REF-Reference (internal unless indicated),2008-07-18T04:00:00Z,2008,7,,,2008-07-18T20:46:02Z,,0,0,0900006480676990
FDA-2005-D-0208-0010,FDA,FDA-2005-D-0208,Background Material  for NAD1 [FDA-2005-D-0208-0002] - Reference List,Supporting & Related Material,BKG-Background Material,2008-07-18T04:00:00Z,2008,7,,,2008-07-18T04:58:02Z,,0,0,0900006480441247
FDA-2005-D-0208-0005,FDA,FDA-2005-D-0208,"Reference 1 - FDA Blood Products Advisory Committee Meeting, March 1999, [FDA-2005-D-0208-0004] - Transcript",Supporting & Related Material,REF-Reference (internal unless indicated),2008-07-18T04:00:00Z,2008,7,,,2008-07-18T20:38:29Z,,0,0,0900006480676030
FDA-2005-D-0208-0012,FDA,FDA-2005-D-0208,Reference 2 - Background Material  for NAD1[FDA-2005-D-0208-0002],Supporting & Related Material,BKG-Background Material,2008-07-18T04:00:00Z,2008,7,,,2008-07-18T04:58:04Z,,0,0,0900006480441248
FDA-2005-D-0208-0013,FDA,FDA-2005-D-0208,"Reference 3 - Background Material  for NAD1 Blood Products Advisory Committee Meeting, March 2000[FDA-2005-D-0208-0002]  - Transcript",Supporting & Related Material,BKG-Background Material,2008-07-18T04:00:00Z,2008,7,,,2008-07-18T04:58:05Z,,0,0,0900006480441245
FDA-2005-D-0208-0004,FDA,FDA-2005-D-0208,"Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency",Other,Guidance,2008-07-17T04:00:00Z,2008,7,2008-07-17T04:00:00Z,,2024-11-12T04:21:43Z,,1,0,0900006480680037
FDA-2005-D-0208-0003,FDA,FDA-2005-D-0208,"Guidance for Industry: Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency; Availability",Notice,NAD-Notice of Availability of Data,2008-07-17T04:00:00Z,2008,7,2008-07-17T04:00:00Z,,2008-07-17T12:54:19Z,E8-16395,0,0,090000648067fb8d
FDA-2005-D-0208-0002,FDA,FDA-2005-D-0208,"Guidance for Industry: Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency; Draft Guidance Document",Other,GDL-Guidance (Supporting and Related Materials),2005-12-02T05:00:00Z,2005,12,,,2008-07-18T05:20:46Z,,0,0,090000648044123a
FDA-2005-D-0208-0001,FDA,FDA-2005-D-0208,"Guidance for Industry: Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency; Availability",Notice,NAD-Notice of Availability of Data,2005-12-02T05:00:00Z,2005,12,2005-11-30T05:00:00Z,2006-03-02T04:59:59Z,2008-07-18T05:09:10Z,,0,0,0900006480441234